Abstract:
Objective To investigate the optimal model of comprehensive therapy for small-cell esophageal carcinoma (SCEC).
Methods The clinical data of 51 SCEC patients who underwent chemotherapy-based comprehensive treatment as the first line of treatment was analyzed retrospectively. We compared the median survival time (MST) of patients among the surgery plus chemotherapy group (S+ C), chemoradiotherapy group (R+C), and surgery plus chemoradiotherapy group (S+R+C).
Results The S+C, R+C, and S+R+C groups comprised 29, 16, and 6 cases, respectively. The MST of the 51 patients was 13.6 months, and the one-, two- and three-year survival rates were 56.5%, 22.4%, and 9.6%, respectively. No significant difference in the distribution of clinical characteristics was found among the three groups (P>0.05). The R+C group contained more cases in the extensive stage (P < 0.05). The MST of the S+C, R+C, and S+R+C groups were 13.3, 13.1, and 14.2 months, respectively, with no significant difference (P=0.626).
Conclusion Chemoradiotherapy is an effective way of treating SCEC; it can achieve similar survival benefits as surgery plus chemotherapy.
下载: